Phase 2 Study of Parsaclisib (INCB050465), a Highly Selective, Next-Generation PI3Kδ Inhibitor, in Relapsed or Refractory Diffuse Large B-cell Lymphoma (CITADEL-202)
Leukemia & lymphoma/Leukemia and lymphoma（2020）
关键词
B-cell lymphoma,DLBCL,INCB050465,non-Hodgkin lymphoma,parsaclisib,PI3Kδ,inhibitor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要